https://scholars.lib.ntu.edu.tw/handle/123456789/537534
標題: | High incidence of CD56 expression and relapse rate in acute myeloid leukemia patients with t(8;21) in Taiwan | 作者: | Hsiao C.-H. JIH-LUH TANG MING YAO WOEI TSAY Wang C.-H. YAO-CHANG CHEN MING-CHING SHEN HWEI-FANG TIEN |
公開日期: | 2002 | 卷: | 101 | 期: | 6 | 起(迄)頁: | 393-398 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background and Purpose: CD56 is a marker of natural killer cells, but can also be found on blast cells in acute myeloid leukemia (AML). The prognostic implications of CD56 expression in AML are not clear. In this study, we evaluated the correlation among CD56 expression, cytogenetic abnormality, and clinical outcome in AML. Methods: CD56 expression was analyzed in leukemic cells from 94 adults with primary AML in Taiwan and was correlated with clinical and hematologic features, cytogenetics, and immunophenotypes of the leukemia. Results: Thirty patients (32%) showed CD56 expression. CD56+ AML patients had a higher lactate dehydrogenase level than CD56- patients (1,136 vs 730 U/L, p = 0.048). Patients with t(8;21) had a significantly higher incidence (89%, 8/9) of CD56 positivity in leukemic cells than those with normal karyotype or other cytogenetic abnormalities (26%, 22/85, p<0.001). In general, there was no different in overall survival time in CD56+ and CD56- AML patients. However, three patients had central nervous system involvement at initial presentation; two of these had concomitant CD56 expression and t(8;21). In addition, five of the seven patients with t(8;21) and CD56 expression who achieved complete remission later relapsed. Conclusions: The incidence of CD56 expression in AML patients with t(8;21) is very high in Taiwan, and it may imply a poor prognosis in this subgroup of patients. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036341728&partnerID=40&md5=3ad24496ab22442ae4aaff3ca0f2c5f1 https://scholars.lib.ntu.edu.tw/handle/123456789/537534 |
ISSN: | 0929-6646 | SDG/關鍵字: | anthracycline; antineoplastic agent; CD56 antigen; cytarabine; doxorubicin; idarubicin; lactate dehydrogenase; retinoic acid; acute granulocytic leukemia; adolescent; adult; aged; antigen expression; article; cancer recurrence; central nervous system disease; chromosome translocation 8; chromosome translocation 9; clinical feature; controlled study; correlation function; cytogenetics; female; genetic disorder; hematology; hematopoietic stem cell transplantation; human; immunophenotyping; incidence; karyotype; leukemia cell; leukemia remission; major clinical study; male; prognosis; recurrence risk; survival time; Taiwan; treatment outcome; Acute Disease; Adolescent; Adult; Aged; Antigens, CD56; Female; Humans; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Recurrence; Survival Rate; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。